Board/Management Information • Nov 21, 2022
Board/Management Information
Open in ViewerOpens in native device viewer
PRESS RELEASE
Montpellier, November 21, 2022 - 6:00pm - MEDESIS PHARMA, a pharmaceutical biotechnology company developing drug candidates based on its proprietary technology for the buccal delivery of active ingredients in nano-micelles, Aonys, announces the constitution of a Permanent Scientific Advisory Board to support the Company in its research and clinical programs dedicated to neurodegenerative diseases.
The mission of the Permanent Scientific Advisory Board is to support Medesis Pharma's Board of Directors by providing advice and guidance on the company's research and development strategy, specifically in the area of Alzheimer's and Huntington's disease. New data generated, development programs and study plans will be discussed within this group to guide Medesis Pharma's strategy in the development of Nanolithium. This board will contribute to the academic and scientific quality of Medesis Pharma's development programs for the treatment of neurodegenerative diseases, in particular Alzheimer's disease, which currently affects more than 55 million people worldwide
Jean Claude Maurel, Chairman of the Executive Board of Medesis Pharma, commented: "We are honored to be supported by a scientific advisory board composed of international experts in neurology, including clinicians and
researchers with expertise in Alzheimer's and Huntington's disease, and promoters of Nanolithium as a potent candidate, we strongly value the field perspective in our development approaches.'
The Permanent Scientific Advisory Board of Medesis Pharma is composed of six internationally renowned personalities in the field of neurodegenerative diseases, particularly Alzheimer's disease and Huntington's disease:
Professor Jacques Touchon is a neuropsychiatrist specialized in Alzheimer's disease. He is emeritus professor at the University of Medicine of Montpellier
He is a founding member and co-chairman of CTAD (Clinical Trial on Alzheimer's Disease) and coeditor-in-chief of JPAD (Journal of Prevention of Alzheimer's Disease).
Professor Eugenia Maria Soto Martin is a geriatrician and gerontologist at the Gerontopole of the Toulouse University Hospital. She is the director of the Alzheimer's Acute Care Unit of the Geriatric
Service of the Toulouse University Hospital and the Regional Aging Team (ERVPD) of the Toulouse
Gerontopole. Prof. Soto neuropsychiatric symptoms. Prof. Soto's expertise in behavioral and psychiatric disorders associated with dementia is nationally recognized.
Dr. Edward Wilson is Professor of Neuroscience at Stanford University in California, USA.
His research focuses on in vivo studies of the pathophysiological mechanisms of Alzheimer's disease, and potential therapeutic options. Dr. Wilson, as part of Prof. Cuello's team at McGill University in Montreal, CA, condu
<sup>1 World Alzheimer Report 2022: https://www.alzint.org/u/World-Alzheimer-Report-2022.pdf
Professor Guy Rouleau is a neurologist and geneticist. He is Professor of Medicine at the University of Montreal and Director of the Sainte-Justine UHC Research Centre, the Centre of Excellence in
Neurology at the University of Montreal and the Quebec Network of Applied Genetic Medicine.
Dr. Rouleau's research interests include the genetic factors involved in brain and nervous system diseases (such as autism, Gilles-de-la-Tourette syndrome, muscular impatience syndrome and schizophrenia). Dr. Rouleau is on the editorial board of major scientific journals, including Neurology of Disease and Annals of Human Genetics. He is a member of several international scientific
committees, and serves on the board of several foundations and societies dedicated to finding cures for nervous
system diseases, such as the Coudé Twins Foundation, or the Canadian Academy of Health Sciences.
Dr. Cecilia Marelli is a neurologist at the Neurology Unit of the Gui de Chauliac Hospital in Montpellier.
Dr. Marelli is interested in the genetic and metabolic components of neurodegenerative diseases, including Huntington's disease, cerebellar ataxias and spastic paraplegia. She directs the Montpellier Center of Expertise on Neurogenetic Diseases and the Montpellier Center of Expertise on Huntington's Disease.
Dr. Mahmoud Pouladi is an Associate Professor of Medical Genetics at Columbia University in Canada. He is a member of the BC Children's Research Institute (BCCHRI) and the Djavad
Mowafaghian Centre for Brain Health in Vancouver.
Dr. Pouladi's research focuses on the pathophysiological mechanisms of Huntington's disease and
the effects of potential therapeutic options. Dr. Pouladi, as part of Prof. Hayden's team at BCCHRI, conducted the proof-of-concept studies on Nanolithium in Huntington's disease.
To advance the treatment of serious diseases without effective treatments, Medesis Pharma creates drug candidates based on its proprietary Aonys® technology for the oral administration of active ingredients in nanodroplet form, enabling active ingredients to be effectively delivered to all cells, with passage through the blood-brain barrier (BBB).
This innovative approach is being applied to future drugs to treat major diseases that do not have effective treatments: Alzheimer's disease, Huntington's disease, and certain resistant cancers.
Medesis Pharma is also developing treatments dedicated to populations contaminated or irradiated after a civil or military nuclear accident.
French biopharmaceutical company based near Montpellier, Medesis Pharma is the author of 15 scientific publications, holds 11 patent families and 71 patents, the result of 17 years of research.
Medesis Pharma's shares are listed on Euronext Growth Paris: FR001844464 - ALMDP
For more information: www.medesispharma.com
MEDESIS PHARMA Tessa Olivato Tel: +33 4 67 03 03 96 [email protected]
CALYPTUS Marie Calleux Tel: +33 1 53 65 68 66 [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.